Sodium colistimethate + Tetracycline + Chloramphenicol (Colistimethatum natricum + Tetracyclinum + Chloramphenicolum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Ophthalmic products

Other antimicrobial, antiparasitic and anthelmintic agents

Included in the formulation
  • Colbiocin
    ointment d / eye 
    SIIFI SpA     Italy
    • АТХ:

    S.01.A.A.20   Antibotics in combination with other drugs

    Pharmacodynamics:

    Cyclic polypeptide antibiotic formed Bacillus polymyxa, subspecies colistinus. The mechanism of action is mainly due to the ability to bind to phospholipids of bacterial cell membranes, which leads to their destruction.

    Active with most gram-negative bacteria, especially - Pseudomonas aeruginosa and Haemophilus influenzae.

    Inactive for Staphylococcus aureus, Serratia marcescens, Providencia spp., Bacteroides fragilis, Neisseria spp., obligate anaerobes and Gram-positive bacteria.

    Has cross-resistance with polymyxin B.

    Chloramphenicol - a broad-spectrum antibiotic, inhibits the synthesis of proteins of sensitive microorganisms; is active against Gram-positive and Gram-negative bacteria, Mycoplasma spp., Rickettsia spp., Chlamydia spp.; is inactive for Pseudomonas aeruginosa, mushrooms.

    Tetracycline, a broad-spectrum antibiotic, inhibiting bacterial protein synthesis at the RNA level, has a bacteriostatic effect. It is active against gram-negative bacteria, Chlamydia spp., Mycoplasma spp., Rickettsia spp., Entamoeba histolytica. Stability of microorganisms develops slowly.

    Pharmacokinetics:

    After inhalation, the absorption of sodium colistimethate has distinct individual differences. Cmax in plasma after inhalation at a dose of 2 million units, it is 280 μg / l (which indicates absorption of less than 2% compared with parenteral administration). After inhalation 2 million units of sodium colistimetate, the average cumulative rate of excretion by the kidneys is about 1%.

    After inhalation of 1 million units of ED, colistimetate sodium concentration in sputum after 1 hour and 4 hours - 183.6 mg / L and 22.8 mg / L, respectively. In the lung, about 1.5% of the administered dose is cumulated.

    Sodium colistimethate penetrates the placenta and is excreted in breast milk.

    Sodium colistimethate is excreted with expectorated sputum. A small part of the drug that enters the systemic circulation is excreted mainly by glomerular filtration. Within 8 hours, kidneys in unchanged form displays about 60% of the dose received.

    Indications:

    Conjunctivitis (catarrhal, purulent, trachomatic); blepharitis; blepharoconjunctivitis; bacterial keratitis; septic ulcer of the cornea; dacryocystitis.

    ICD-10

    VII.H10-H13.H10.5   Blepharoconjunctivitis

    VII.H00-H06.H01.0   Blepharitis

    VII.H15-H22.H19.2 *   Keratitis and keratoconjunctivitis in other infectious and parasitic diseases classified elsewhere

    VII.H15-H22.H19.1 *   Keratitis due to herpes simplex virus, and keratoconjunctivitis (B00.5 +)

    XII.L80-L99.L86 *   Keratoderma in diseases classified elsewhere

    VII.H15-H22.H16.9   Keratitis, unspecified

    VII.H15-H22.H16.8   Other forms of keratitis

    VII.H15-H22.H16.2   Keratoconjunctivitis

    VII.H15-H22.H16.1   Other superficial keratitis without conjunctivitis

    VII.H15-H22.H16   Keratite

    VII.H15-H22.H16.0   Corneal ulcer

    VII.H00-H06.H04.3   Acute and unspecified inflammation of lacrimal ducts

    Contraindications:

    Hypersensitivity; impaired liver function, kidney function; pregnancy; lactation period; children's age (up to 8 years).

    Carefully:

    Children under 18 years.

    Pregnancy and lactation:

    Category FDA not determined.

    Contraindicated in pregnancy. For the duration of treatment, breastfeeding should be discontinued.

    Dosing and Administration:

    Eye Drops

    Conjunctival, 1-2 drops 3-4 times a day or according to the individual prescription of the treating doctor.

    Terms of use of the bottle

    1. Following the existing notches on the aluminum capsule of the vial, tear off the upper circumference of the capsule, and then - the side.

    2. Remove the lid from the vial and adjust the reservoir to it.

    3. Press the red tank cover into the vial, and then vigorously shake the vial to dissolve the powder in it.

    4.Remove completely the reservoir and put the dropper (pipette) on the vial. Remove the cap from the dropper (pipette) and, turning the bottle, squeeze a drop.

    Eye Ointment: lay in the lower conjunctival arch 3-4 times a day. When combined with the use of eye drops, the use of eye ointment is sufficient once a night.

    Side effects:

    Eye drops contain sodium sulfite, this component of the drug can provoke allergic reactions and severe asthma attacks in sensitive individuals (especially asthmatics).

    Since rare cases of bone marrow hypoplasia have been reported due to prolonged topical application of chloramphenicol, the drug should be used for short periods of time and under the supervision of an ophthalmologist.

    Prolonged local use of antibiotics can cause symptoms of local irritation (short-term conjunctival hyperemia). The cases of the appearance of symptoms of hypersensitivity in the form of burning, angioedema, urticaria, bullous and spottypapular dermatitis are registered, which requires discontinuation of the drug.

    Overdose:

    Not described.

    Interaction:

    At local application of pharmacological interactions with other preparations it is not revealed.

    Special instructions:

    In the absence of significant clinical improvement over a relatively short period of time or the appearance of allergic reactions to the components of the drug, it is necessary to interrupt treatment and prescribe appropriate therapy.

    Instructions
    Up